HUMAN MICROBIOTA AND BREAST CANCER.

Q3 Medicine

Experimental oncology Pub Date : 2022-08-01 DOI:10.32471/exp-oncology.2312-8852.vol-44-no-2.17855

Yu V Shvets, O O Lykhova, V F Chekhun

引用次数: 4

Abstract

Breast cancer is the leading malignancy in women worldwide. To date, much is known about the molecular subtypes of these malignant neoplasms and the mechanisms of drug resistance. Significant success has been achieved in approaches to early diagnosis, which allows identifying the tumor process in the early stages of development. Recently, the study of the influence of the human body microbiota on cancer development and the effectiveness of treatment has become an actively developing field of research. This review presents an analysis of the literature data on this issue.

查看原文本刊更多论文

人类微生物群和乳腺癌。

乳腺癌是全世界妇女的主要恶性肿瘤。迄今为止，对这些恶性肿瘤的分子亚型和耐药性机制了解甚多。在早期诊断方法方面取得了重大成功，可以在发展的早期阶段识别肿瘤进程。近年来，研究人体微生物群对癌症发展和治疗效果的影响已成为一个积极发展的研究领域。本文对这一问题的文献资料进行了分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.